Big pharma, Partnering, Pharma

GSK announces grant to IAVI for human vaccines project

Posted on 18 February 2015

Tags: , ,

The International AIDS Vaccine Initiative has received a grant of US$350,000 from GSK to support implementation of the Human Vaccines Project, a new public-private partnership seeking to transform global disease prevention by collaboratively addressing some of the key scientific challenges in vaccine development across diseases.

The GSK grant will help to establish the Project's global consortium and plan its research program.

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
  • CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time

The grant builds on a funding last year to IAVI by the Robert Wood Johnson Foundation for a series of workshops to explore how to accelerate development of vaccines via a Human Vaccines Project, by tackling the major scientific challenges impeding vaccine research and development through greater collaboration, increased knowledge sharing, and innovation.

The Project's objectives are to facilitate development of new and improved vaccines by deciphering the "Human Immunome," all the genes and proteins associated with the human immune system, and elucidating the "Rules of Immunogenicity", i.e., how humans generate effective immune responses with vaccines.

Thus, the Project aims to address the common scientific obstacles preventing development of vaccines against major and emerging infectious diseases and cancers complementing ongoing disease-specific vaccine development efforts.

For further deal information visit Current Agreements (subscription required)

Related

Scorecard: Top partnering deals by value in 2015

View: Top pharmaceutical companies

View: Top biotech companies

Reports: Browse our extensive deal making report portfolio

 

Print Friendly, PDF & Email

Leave a Reply